A Study of MM-121 in Combination With Paclitaxel in Patients With Advanced Gynecologic and Breast Cancers
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Locally Advanced/Metastatic or Recurrent Ovarian Cancer, Fallopian Tube Cancer,|Primary Peritoneal Cancer or Endometrial Cancer|Locally Advanced/Metastatic Her2 Non Overexpressing Breast Cancer
Interventions: DRUG: MM-121|DRUG: Paclitaxel
Sponsor: Merrimack Pharmaceuticals
Collaborators: Sanofi